nach oben

Breast Cancer Research and Treatment

Erschienen in:

01.05.2012 | Review

Role of interleukin-10 in breast cancer

verfasst von: Hamidullah, Bendangla Changkija, Rituraj Konwar

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Cytokines are low molecular weight regulatory proteins or glycoprotein that modulates the intensity and duration of immune response by stimulating or inhibiting the activation, proliferation, and/or differentiation of target cells. Different cytokines are known to have diverse role in breast cancer initiation and progression. Interleukin-10 (IL-10), a pleiotropic anti-inflammatory cytokine, induces immunosuppression and assists in escape from tumor immune surveillance. Like several other cytokines, IL-10 also can exert dual proliferative and inhibitory effect on breast tumor cells indicating a complex role of IL-10 in breast cancer initiation and progression. In this review, we tried to put together a comprehensive current view on significance of IL-10 in promotion, inhibition, and importance as prognosticator in breast cancer based on in vitro, in vivo, and clinical evidences. For literature collection, we conducted PubMed search with keywords “IL-10” and “breast cancer”.

Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef

Parkin DM, Fernandez LM (2006) Use of statistics to assess the global burden of breast cancer. Breast J 12(Suppl. 1):70–80CrossRef

Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y (2004) Cytokines in cancer immunity and immunotherapy. Immunol Rev 202:275–293PubMedCrossRef

Standish LJ, Sweet ES, Novack J, Wenner CA, Bridge C, Nelson A, Martzen M, Torkelson C (2008) Breast cancer and the immune system. J Soc Integr Oncol 6(4):158–168PubMed

DeNardo DG, Coussens LM (2007) Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9(4):212PubMedCrossRef

Rao VS, Dyer CE, Jameel JK, Drew PJ, Greenman J (2006) Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). Oncol Rep 15(1):179–185PubMed

Carpi A, Nicolini A, Antonelli A, Ferrari P, Rossi G (2009) Cytokines in the management of high risk or advanced breast cancer: an update and expectation. Curr Cancer Drug Target 9(8):888–903CrossRef

Konwar R, Chaudhary P, Kumar S, Mishra D, Chattopadhyay N, Bid HK (2009) Breast cancer risk associated with polymorphisms of IL-1RN and IL-4 gene in Indian women. Oncol Res 17(8):367–372PubMedCrossRef

Moore KW, O’Garra A, de Waal MR, Vieira P, Mosmann TR (1993) Interleukin-10. Annu Rev Immunol 11:165–190PubMedCrossRef

10.

Fitzgerald KA, O’Neill LAJ, Gearing AJH, Callard RE (2001) The cytokine facts book, 2nd edn. Academic Press, London

11.

Lentsch AB, Shanley TP, Sarma V, Ward PA (1997) In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest 100(10):2443–2448PubMedCrossRef

12.

Kotenko SV, Krause CD, Izotova LS, Pollack BP, Wu W, Pestka S (1997) Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J 16(19):5894–5903PubMedCrossRef

13.

Mosmann TR (1994) Properties and functions of interleukin-10. Adv Immunol 56:1–26PubMedCrossRef

14.

Howard M, O’Garra A (1992) Biological properties of interleukin 10. Immunol Today 13(6):198–200PubMedCrossRef

15.

Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683–765PubMedCrossRef

16.

Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB (2004) Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22:929–979PubMedCrossRef

17.

Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG (2011) Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 29:71–109PubMedCrossRef

18.

de Waal Malefyt R, Yssel H, Roncarolo MG, Spits H, de Vries JE (1992) Interleukin-10. Curr Opin Immunol 4(3):314–320PubMedCrossRef

19.

Asadullah K, Sterry W, Volk HD (2003) Interleukin-10 therapy—review of a new approach. Pharmacol Rev 55(2):241–269PubMedCrossRef

20.

Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J (2010) Biology of interleukin-10. Cytokine Growth Factor Rev 21(5):331–344PubMedCrossRef

21.

Wolk K, Kunz S, Asadullah K, Sabat R (2002) Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 168(11):5397–5402PubMed

22.

Couper KN, Blount DG, Riley EM (2008) IL-10: the master regulator of immunity to infection. J Immunol 180(9):5771–5777PubMed

23.

O’Garra A, Vieira P (2007) TH1 cells control themselves by producing interleukin-10. Nat Rev Immunol 7:425–428PubMedCrossRef

24.

Ho AS, Wei SH, Mui AL, Miyajima A, Moore KW (1995) Functional regions of the mouse interleukin-10 receptor cytoplasmic domain. Mol Cell Biol 15:5043–5053PubMed

25.

Finbloom DS, Winestock KD (1995) IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J Immunol 155(3):1079–1090PubMed

26.

Lai CF, Ripperger J, Morella KK, Jurlander J, Hawley TS, Carson WE, Kordula T, Caligiuri MA, Hawley RG, Fey GH, Baumann H (1996) Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements. J Biol Chem 271(24):13968–13975PubMedCrossRef

27.

Williams LM, Ricchetti G, Sarma U, Smallie T, Foxwell BM (2004) Interleukin-10 suppression of myeloid cell activation—a continuing puzzle. Immunology 113(3):281–292PubMedCrossRef

28.

Braunschweig A, Poehlmann TG, Busch S, Schleussner E, Markert UR (2011) Signal transducer and activator of transcription 3 (STAT3) and suppressor of cytokine signaling (SOCS3) balance controls cytotoxicity and IL-10 expression in decidual-like natural killer cell line NK-92. Am J Reprod Immunol 66(3):329–335PubMedCrossRef

29.

Lee EB, Kim A, Kang K, Kim H, Lim JS (2010) NDRG2-mediated modulation of SOCS3 and STAT3 activity inhibits IL-10 production. Immune Netw 10(6):219–229PubMedCrossRef

30.

Haddad JJ, Saadé NE, Safieh-Garabedian B (2003) Interleukin-10 and the regulation of mitogen-activated protein kinases: are these signalling modules targets for the anti-inflammatory action of this cytokine? Cell Signal 15(3):255–267PubMedCrossRef

31.

Kruger-Krasagakes S, Krasagakis K, Garbe C, Schmitt E, Hüls C, Blankenstein T, Diamantstein T (1994) Expression of interleukin 10 in human melanoma. Br J Cancer 70(6):1182–1185PubMedCrossRef

32.

Gastl GA, Abrams JS, Nanus DM, Oosterkamp R, Silver J, Liu F, Chen M, Albino AP, Bander NH (1993) Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 55(1):96–101PubMedCrossRef

33.

Joimel U, Gest C, Soria J, Pritchard LL, Alexandre J, Laurent M, Blot E, Cazin L, Vannier JP, Varin R et al (2010) Stimulation of angiogenesis resulting from cooperation between macrophages and MDA-MB-231 breast cancer cells: proposed molecular mechanism and effect of tetrathiomolybdate. BMC Cancer 10:375PubMedCrossRef

34.

Venetsanakos E, Beckman I, Bradley J, Skinner JM (1997) High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer 75(12):1826–1830PubMedCrossRef

35.

Al-Sarireh B, Sathaporn S, Robins A, Jenkin D, Vassanasiri W, El-Sheemy M, Jibril JA, Clark D, Eremin O (2010) Mononuclear phagocytes but not tumour cells are the main source of elevated inter-leukin (IL)-10 levels in human breast cancer. Surgeons in training 2000. The Royal College of Surgeons of Edinburgh. Retrieved on 02 December 2010 from http://www.rcsed.ac.uk/Journal/vol46_1/4610011.htm

36.

Bogdan C, Vodovotz Y, Nathan C (1991) Macrophage deactivation by interleukin 10. J Exp Med 174(6):1549–1555PubMedCrossRef

37.

Hashimoto SI, Komuro I, Yamada M, Akagawa KS (2001) IL-10 inhibits granulocyte-macrophage colony-stimulating factor-dependent human monocyte survival at the early stage of the culture and inhibits the generation of macrophages. J Immunol 167(7):3619–3625PubMed

38.

Commeren DL, Van Soest PL, Karimi K, Löwenberg B, Cornelissen JJ, Braakman E (2003) Paradoxical effects of interleukin-10 on the maturation of murine myeloid dendritic cells. Immunology 110(2):188–196PubMedCrossRef

39.

de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, de Vries JE (1991) Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174(4):915–924PubMedCrossRef

40.

Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O’Garra A (1991) IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 146(10):3444–3451PubMed

41.

Macatonia SE, Doherty TM, Knight SC, O’Garra A (1993) Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFN-gamma production. J Immunol 150(9):3755–3765PubMed

42.

de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE (1991) Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174(5):1209–1220PubMedCrossRef

43.

Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O’Garra A (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147(11):3815–3822PubMed

44.

Jenkins JK, Malyak M, Arend WP (1994) The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. Lymphokine Cytokine Res 13(1):47–54PubMed

45.

Huber S, Gagliani N, Esplugues E, O’Connor W Jr, Huber FJ, Chaudhry A, Kamanaka M, Kobayashi Y, Booth CJ, Rudensky AY et al (2011) Th17 cells express interleukin-10 receptor and are controlled by Foxp3⁻ and Foxp3⁺ regulatory CD4⁺ T cells in an interleukin-10-dependent manner. Immunity 34(4):554–565PubMedCrossRef

46.

Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT, Brüning JC, Müller W et al (2011) Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34(4):566–578PubMedCrossRef

47.

Scott DE, Gause WC, Finkelman FD, Steinberg AD (1990) Anti-CD3 antibody induces rapid expression of cytokine genes in vivo. J Immunol 145(7):2183–2188PubMed

48.

Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker SM, Francis JN, Durham SR (2007) Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol 178(7):4658–4666PubMed

49.

Geissmann F, Launay P, Pasquier B, Lepelletier Y, Leborgne M, Lehuen A, Brousse N, Monteiro RC (2001) A subset of human dendritic cells expresses IgA Fc receptor (CD89), which mediates internalization and activation upon cross-linking by IgA complexes. J Immunol 166(1):346–352PubMed

50.

McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T, Cua DJ (2007) TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 8(12):1390–1397PubMedCrossRef

51.

Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, Flavell RA, Kuchroo VK, Oukka M, Weiner HL (2007) A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol 8(12):1380–1389PubMedCrossRef

52.

Fitzgerald DC, Zhang GX, El-Behi M, Fonseca-Kelly Z, Li H, Yu S, Saris CJ, Gran B, Ciric B, Rostami A (2007) Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 8(12):1372–1379PubMedCrossRef

53.

Pang G, Couch L, Batey R, Clancy R, Cripps A (1994) GM-CSF, IL-1 alpha, IL-1 beta, IL-6, IL-8, IL-10, ICAM-1 and VCAM-1 gene expression and cytokine production in human duodenal fibroblasts stimulated with lipopolysaccharide, IL-1 alpha and TNF-alpha. Clin Exp Immunol 96(3):437–443PubMedCrossRef

54.

Kim KH, Kim DI, Kim SH, Jung EM, Kang JH, Jeung EB, Yang MP (2011) Trans-10, cis-12-conjugated linoleic acid attenuates tumor necrosis factor-α production by lipopolysaccharide-stimulated porcine peripheral blood mononuclear cells through induction of interleukin-10. Cytokine; doi:10.1016/j.cyto.2011.06.019

55.

Brunsing RL, Prossnitz ER (2011) Induction of interleukin-10 in the T helper type 17 effector population by the G protein coupled estrogen receptor (GPER) agonist G-1. Immunology 134(1):93–106PubMedCrossRef

56.

Lazarini M, Traina F, Winnischofer SM, Costa FF, Queiroz ML, Saad ST (2011) Effects of thalidomide on long-term bone marrow cultures from patients with myelodysplastic syndromes: induction of IL-10 expression in the stromal layers. Leuk Res 35(8):1102–1107PubMedCrossRef

57.

Lian ZR, Xu YF, Wang XB, Gong JP, Liu ZJ (2011) Suppression of Histone Deacetylase 11 Promotes Expression of IL-10 in Kupffer Cells and Induces Tolerance Following Orthotopic Liver Transplantation in Rats. J Surg Res; doi:10.1016/j.jss.2010.12.035

58.

Municio C, Hugo E, Alvarez Y, Alonso S, Blanco L, Fernández N, Sánchez Crespo M (2011) Apoptotic cells enhance IL-10 and reduce IL-23 production in human dendritic cells treated with zymosan. Mol Immunol; doi:10.1016/j.molimm.2011.07.022

59.

Xu J, Yang Y, Qiu G, Lal G, Wu Z, Levy DE, Ochando JC, Bromberg JS, Ding Y (2009) c-Maf regulates IL-10 expression during Th17 polarization. J Immunol 182(10):6226–6236PubMedCrossRef

60.

Durez P, Abramowicz D, Gérard C, Van Mechelen M, Amraoui Z, Dubois C, Leo O, Velu T, Goldman M (1993) In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: differential modulation by cyclosporin A. J Exp Med 177(2):551–555PubMedCrossRef

61.

Ji JD, Kim HJ, Rho YH, Choi SJ, Lee YH, Cheon HJ, Sohn J, Song GG (2005) Inhibition of IL-10-induced STAT3 activation by 15-deoxy-Delta12, 14-prostaglandin J2. Rheumatology (Oxford) 44(8):983–988CrossRef

62.

Kalechman Y, Gafter U, Weinstein T, Chagnac A, Freidkin I, Tobar A, Albeck M, Sredni B (2004) Inhibition of interleukin-10 by the immunomodulator AS101 reduces mesangial cell proliferation in experimental mesangioproliferative glomerulonephritis: association with dephosphorylation of STAT3. J Biol Chem 279(23):24724–24732PubMedCrossRef

63.

Alas S, Emmanouilides C, Bonavida B (2001) Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clin Cancer Res 7(3):709–723PubMed

64.

Kundu N, Beaty TL, Jackson MJ, Fulton AM (1996) Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst 88(8):536–541PubMedCrossRef

65.

Mocellin S, Marincola FM, Young HA (2005) Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol 78(5):1043–1051PubMedCrossRef

66.

Pinzon-Charry A, Maxwell T, López JA (2005) Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 83(5):451–461PubMedCrossRef

67.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674PubMedCrossRef

68.

Cohen SB, Crawley JB, Kahan MC, Feldmann M, Foxwell BM (1997) Interleukin-10 rescues T cells from apoptotic cell death: association with an upregulation of Bcl-2. Immunology 92:1–5PubMedCrossRef

69.

Taga K, Cherney B, Tosato G (1993) IL-10 inhibits apoptotic cell death in human T cells starved of IL-2. Int Immunol 5:1599–1608PubMedCrossRef

70.

Alas S, Bonavida B (2001) Rituximab inactivates signal transducer and activation of transcription 3 (stat3) activity in b-nonhodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61:5137–5144PubMed

71.

Wang XZ, Zhang SJ, Chen YX, Chen ZX, Huang YH, Zhang LJ (2004) Effects of platelet-derived growth factor and interleukin-10 on Fas/Fas-ligand and Bcl-2/Bax mRNA expression in rat hepatic stellate cells in vitro. World J Gastroenterol 10:2706–2710PubMed

72.

Zeng L, O’Connor C, Zhang J, Kaplan AM, Cohen DA (2010) IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines. Cytokine 49(3):294–302PubMedCrossRef

73.

Fox JG, Sheppard BJ, Dangler CA, Whary MT, Ihrig M, Wang TC (2002) Germ-line p53-targeted disruption inhibits helicobacter induced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 proinflammatory responses. Cancer Res 62:696–702PubMed

74.

Okuda Y, Okuda M, Bernard CC (2003) Regulatory role of p53 in experimental autoimmune encephalomyelitis. J Neuroimmunol 135:29–37PubMedCrossRef

75.

Ohkuso-Tsukada K, Tsukada T, Isobe KI (1999) Accelerated development and aging of the immune system in p53-deficient mice. J Immunol 163:1966–1972

76.

Kohno T, Mizukami H, Suzuki M, Saga Y, Takei Y, Shimpo M, Matsushita T, Okada T, Hanazono Y, Kume A, Sato I, Ozawa K (2003) Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res 63(16):5091–5094PubMed

77.

Stearns ME, Rhim J, Wang M (1999) Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion. Clin Cancer Res 5(1):189–196PubMed

78.

García-Hernández ML, Hernández-Pando R, Gariglio P, Berumen J (2002) Interleukin-10 promotes B16-melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation. Immunology 105(2):231–243PubMedCrossRef

79.

Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M (1996) Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin Cancer Res 2(12):1969–1979PubMed

80.

Fujii S, Shimizu K, Shimizu T, Lotze MT (2001) Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood 98(7):2143–2151PubMedCrossRef

81.

Segal BM, Glass DD, Shevach EM (2002) Cutting edge: IL-10-producing CD4⁺ T cells mediate tumor rejection. J Immunol 168(1):1–4PubMed

82.

Garcia-Lora A, Algarra I, Garrido F (2003) MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 195(3):346–355PubMedCrossRef

83.

Di Carlo E, Coletti A, Modesti A, Giovarelli M, Forni G, Musiani P (1998) Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection. Eur Cytokine Netw 9(1):61–68PubMed

84.

Kaufman HL, Rao JB, Irvine KR, Bronte V, Rosenberg SA, Restifo NP (1999) Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. J Immunother 22(6):489–496PubMedCrossRef

85.

Dorsey R, Kundu N, Yang Q, Tannenbaum CS, Sun H, Hamilton TA, Fulton AM (2002) Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma. Cancer Res 62(9):2606–2610PubMed

86.

Allione A, Consalvo M, Nanni P, Lollini PL, Cavallo F, Giovarelli M, Forni M, Gulino A, Colombo MP, Dellabona P et al (1994) Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Cancer Res 54(23):6022–6026PubMed

87.

Giovarelli M, Musiani P, Modesti A, Dellabona P, Casorati G, Allione A, Consalvo M, Cavallo F, di Pierro F, De Giovanni C (1995) Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 155(6):3112–3123PubMed

88.

Kundu N, Dorsey R, Jackson MJ, Guiterrez P, Wilson K, Fu S, Ramanujam K, Thomas E, Fulton AM (1998) Interleukin-10 gene transfer inhibits murine mammary tumors and elevates nitric oxide. Int J Cancer 76(5):713–719PubMedCrossRef

89.

Paul S, Biswas A, Sasmal K, Mukherjee S, Biswas T, Biswas R (2010) IL-10 alters prolactin receptor activity emulating that during breast cancer. Cytokine 51(2):144–150PubMedCrossRef

90.

Halak BK, Maguire HC Jr, Lattime EC (1999) Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res 59(4):911–917PubMed

91.

Abbas AK, Lichtman AH (2006) Cellular and molecular immunology, 5th edn. Elsevier, Amsterdam

92.

Knüpfer H, Preiss R (2007) Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 102:129–135PubMedCrossRef

93.

Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334(Pt 2):297–314PubMed

94.

Kovacs E (2001) Investigation of interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R) and soluble gp130 (sgp130) in sera of cancer patients. Biomed Pharmacother 55(7):391–396PubMedCrossRef

95.

Kozłowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ (2003) Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst 48:82–84PubMed

96.

Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, Roques S, Lazennec G (2007) Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 9(1):R15PubMedCrossRef

97.

Lyon DE, McCain NL, Walter J (2008) Cytokine comparison between women with breast cancer and women with a negative breast biopsy. Nurs Res 57(1):51–58PubMedCrossRef

98.

Akbulut H, Tang Y, Akbulut KG, Maynard J, Deisseroth A (2008) Chemotherapy targeted to cancer tissue potentiates antigen-specific immune response induced by vaccine for in vivo antigen loading and activation of dendritic cells. Mol Ther 16(10):1753–1760PubMedCrossRef

99.

Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D et al (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25(3):94–102PubMedCrossRef

100.

Lee M, Yea SS, Jeon YJ (2000) Paclitaxel causes mouse splenic lymphocytes to a state hyporesponsive to lipopolysaccharide stimulation. Int J Immunopharmacol 22(8):615–621PubMedCrossRef

101.

Nolen BM, Marks JR, Ta’san S, Rand A, Luong TM, Wang Y, Blackwell K, Lokshin AE (2008) Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res 10(3):R45PubMedCrossRef

102.

Llanes-Fernandez L, Alvarez-Goyanes RI, Arango-Prado Mdel C, Alcocer-Gonzalez JM, Mojarrieta JC, Perez XE, Lopez MO, Odio SF, Camacho-Rodríguez R, Guerra-Yi ME et al (2006) Relationship between IL-10 and tumor markers in breast cancer patients. Breast 15(4):482–489PubMedCrossRef

103.

Merendino RA, Arena A, Capozza AB, Chillemi S, Mesiti M (1996) Serum levels of interleukin-10 in patients affected by breast cancer. Immunol Lett 53(1):59–60PubMedCrossRef

104.

Merendino RA, Gangemi S, Misefari A, Arena A, Capozza AB, Chillemi S, D’Ambrosio FP (1999) Interleukin-12 and interleukin-10 production by mononuclear phagocytic cells from breast cancer patients. Immunol Lett 68(2–3):355–358PubMedCrossRef

105.

Son KS, Kang HS, Kim SJ, Jung SY, Min SY, Lee SY, Kim SW, Kwon Y, Lee KS, Shin KH et al (2010) Hypomethylation of the interleukin-10 gene in breast cancer tissues. Breast 19(6):484–488PubMedCrossRef

106.

Razmkhah M, Jaberipour M, Erfani N, Habibagahi M, Talei AR, Ghaderi A (2011) Adipose derived stem cells (ASCs) isolated from breast cancer tissue express IL-4, IL-10 and TGF-β1 and upregulate expression of regulatory molecules on T cells: do they protect breast cancer cells from the immune response? Cell Immunol 266(2):116–122PubMedCrossRef

107.

Heckel MC, Wolfson A, Slachta CA, Schwarting R, Salgame P, Katsetos CD, Platsoucas CD (2011) Human breast tumor cells express IL-10 and IL-12p40 transcripts and proteins, but do not produce IL-12p70. Cell Immunol 266(2):143–153PubMedCrossRef

108.

Rosen HR, Ausch C, Reinerova M, Zaspin E, Renner K, Rosen AC, Schiessel R, Moroz C (1998) Activated lymphocytes from breast cancer patients express the characteristics of type 2 helper cells—a possible role for breast cancer-associated p43. Cancer Lett 127(1–2):129–134PubMedCrossRef

109.

Rao VS, Alabi A, Dyer CE, Greenman J, Drew PJ (2008) IL-10 and IL-12 expression in breast cancer patients and effect of therapy—ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 26(15S):14016

110.

Santos SCL, Ribeiro EMSF, Cavalli IJ, Lima RS, da Graça Bicalho M (2005) IL-10 gene polymorphisms and sporadic breast cancer. Hum Immunol 66(8), Supplement 1:53

111.

Yu KD, Chen AX, Yang C, Fan L, Huang AJ, Shao ZM (2010) The associations between two polymorphisms in the interleukin-10 gene promoter and breast cancer risk. Breast Cancer Res Treat; doi:10.1007/s10549-010-1133-3

112.

Giordani L, Bruzzi P, Lasalandra C, Quaranta M, Schittulli F, Della Ragione F, Iolascon A (2003) Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. Clin Chem 49(10):1664–1667PubMedCrossRef

113.

Smith KC, Bateman AC, Fussell HM, Howell WM (2004) Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 31(4):167–173PubMedCrossRef

114.

Langsenlehner U, Krippl P, Renner W, Yazdani-Biuki B, Eder T, Köppel H, Wascher TC, Paulweber B, Samonigg H (2005) Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat 90(2):113–115PubMedCrossRef

115.

Kong F, Liu J, Liu Y, Song B, Wang H, Liu W (2010) Association of interleukin-10 gene polymorphisms with breast cancer in a Chinese population. J Exp Clin Cancer Res 29:72PubMedCrossRef

116.

Gerger A, Renner W, Langsenlehner T, Hofmann G, Knechtel G, Szkandera J, Samonigg H, Krippl P, Langsenlehner U (2010) Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Res Treat 119(3):701–705PubMedCrossRef

117.

Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24(1):1–8PubMedCrossRef

118.

Kingo K, Ratsep R, Koks S, Karelson M, Silm H, Vasar E (2005) Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility. J Dermatol Sci 37(2):111–113PubMedCrossRef

119.

Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P (1999) Polymorphic haplotypes of the interleukin-10 50 flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 42(6):1101–1108PubMedCrossRef

120.

Yang CH, Chuang LY, Chen YJ, Tseng HF, Chang HW (2011) Computational analysis of simulated SNP interactions between 26 growth factor-related genes in a breast cancer association study. OMICS 15(6):399–407PubMedCrossRef

Titel: Role of interleukin-10 in breast cancer
verfasst von: Hamidullah
Bendangla Changkija
Rituraj Konwar
Publikationsdatum: 01.05.2012
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1855-x

Springer Medizin

Role of interleukin-10 in breast cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis

The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents

Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04)

Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study

Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients

Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5′-DFUR, the bioactive metabolite of Xeloda®

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie